1. Data & Insights

Four Revelations from Minnesota’s First 340B Transparency Report (rerun)

Written by Posted on Less than 0 min read

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead.

Click here to see the original post from December 2024.

It’s time to pay attention to the money behind the 340B curtain.

Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more.

There are important limitations to these data. But Minnesota’s report marks a valuable first step on the yellow brick road to the wonderful world of transparency. I suspect similar reports are gonna be popular.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 36
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Agencies & Vendors

In an Uncertain 340B Environment, Kalderos Offers a Clear Path Forward

Today’s guest post comes from Angie Franks, Chief Executive Officer at Kalderos. Angie examines the growing uncertainty surrounding the 340B program and explains why comprehensive reform remains unlikely in the near term. She argues that claims-level transparency must serve as the foundation for a sustainable path forward. She describes Truzo, Kalderos’ solution for manufacturers and covered […]
2 min read
0
  1. Data & Insights

The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies

Next week, Drug Channels Institute (DCI) will release our 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 16th edition of our popular and comprehensive examination of the entire U.S. drug pricing, reimbursement, and dispensing system. For 2024, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty […]
3 min read
0
  1. Holiday & Events

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It’s time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats: Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy Vampiric! Prior authorization sinks its fangs into providers’ time Wicked! How the IRA will put a stake through […]
2 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts

Over the summer, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on healthcare. (See links below.) These data provide the latest official and apolitical look at the future of U.S. healthcare spending. The top line projections highlight the government’s official view that prescription drugs dispensed […]
2 min read
0
  1. Department: HBC

As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact

Today’s guest post comes from Lara Loveman, VP of Pharma Solutions at Outcomes. Lara discusses how shifting market forces and evolving reimbursement models are reshaping pharmaceutical marketing strategies. She suggests that pharmacist-led interventions—particularly in chronic disease management—can both protect pharmaceutical investment and drive better health outcomes. Click here to learn about Outcomes’ pharmacist-led interventions solution. […]
2 min read
0
  1. Trends & External Forces

2025 Brand Drug Challenges: A GoodRx Perspective

Today’s guest post is from Dorothy Gemmell, Chief Commercial Officer and President, Manufacturer Solutions, at GoodRx. Dorothy highlights five trends to watch in 2025. She then describes how GoodRx’s Cash Point-of-Sale Solution can help brands improve gross-to-net (GTN) while also making medications more affordable for patients. Click here to download the latest GoodRx data on […]
2 min read
0
  1. Trends & External Forces

Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses

As I’ve been warning for years, the Inflation Reduction Act of 2022 (IRA) has nearly obliterated the stand-alone Medicare Part D prescription drug plan (PDP) market. DCI’s exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals: The number of PDPs has plummeted by 55% since the IRA’s passage, to a record low […]
3 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress

Summer unofficially began over the weekend. To mark the occasion, here are a few hot items, freshly seared on the Drug Channels grill: Reactions from the Drug Channels community to the Most Favored Nation (MFN) pricing policy A reality check on whether plan sponsors truly want rebate reform What plan sponsors should know about the […]
2 min read
0
  1. Data & Insights

Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025

Abracadabra! Small pharmacies have ghosted Medicare Part D’s preferred networks—no farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Today, we update our exclusive analysis of how […]
2 min read
0
  1. Media & Marketing

Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing

Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds John discusses how the new maximum fair prices (MFPs) published by the Centers for Medicaid & Medicare Services (CMS) will affect medication affordability, formulary negotiations, evidence-based strategies, and other aspects of the market. To learn more, register for CoverMyMeds’ […]
2 min read
0
  1. Data & Insights

Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 14, 2025, Drug Channels Institute will release our 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our sixteenth edition—is the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. With 9 chapters, 400+ pages, 187 exhibits, and 850+ endnotes, this report is unmatched in […]
3 min read
0
  1. Channel: Drug

Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channels Outlook 2026 . Today’s rerun provides background for the webinar, when I will discuss how the consequences of the Inflation Reduction Act for the 340B program and contract pharmacies. Click here to see the original post from May […]
2 min read
0
  1. Trends & External Forces

The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions

Reality has again failed to support the spin surrounding the 340B Drug Pricing Program. For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases […]
2 min read
0
  1. Media & Marketing

Drug Channels Leadership Forum: Full Agenda Now Available (Spoiler: It’s Awesome!)

I am pleased to announce the full agenda for the inaugural Drug Channels Leadership Forum, which will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Everyone here at Drug Channels Institute (DCI) is excited to bring this novel event to the drug channels community. I personally assembled […]
3 min read
0
  1. Media & Marketing

Drug Channels News Roundup, June 2025: PBM Rebate Flow, 340B’s 2024 Boom, IRA Fallout, MFN Legal Risks—and Mark Cuban’s PBM Rant

Happy 249th birthday, America! Before you launch your July 4 festivities, Drug Channels humbly offers some fact-based fireworks to heal our troubled nation: Where the Rebates Really Go Another Year of Explosive Growth for the 340B Program IRA Fallout for Seniors’ Out-of-Pocket Drug Costs Most-Favored-Nation Pricing’s Shaky Legal Foundations Plus, Mark Cuban’s blunt take on […]
2 min read
0
  1. Data & Insights

Four Revelations from Minnesota’s First 340B Transparency Report

It’s time to pay attention to the money behind the 340B curtain. Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. There are important […]
2 min read
0
  1. Merchandising

Available for Preorder: The 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 8, 2024, Drug Channels Institute will release our 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 350+ pages, 178 exhibits, 750+ endnotes: There is nothing else available that comes close […]
2 min read
0
  1. Data & Insights

Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different

Today’s guest post is from Dr. Richard Faris, Chief Commercial and Clinical Officer at PANTHERx Rare. Richard examines key considerations in launching rare disease therapies. He  argues that targeted reach, tighter relationships, and data-driven collaboration can improve success for both patients and manufacturers. To learn more, download PANTHERx Rare’s free guide: From PDUFA to Patient: A […]
2 min read
0
  1. Department: HBC

The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2025. The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). Drug […]
2 min read
0
  1. Data & Insights

Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization

Today’s guest post comes from Sean Wagner, VP of Client Partnerships and Carolyn Zele, Advisor, Solution Consulting at MMIT. Sean and Carolyn argue that planning for a successful drug launch must begin early—often well before Phase III. In this article, they present a six-step framework to help manufacturers align clinical development with payer expectations, patient […]
2 min read
0
Next